Literature DB >> 21274004

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases.

V Grossmann, A Kohlmann, M Zenger, S Schindela, C Eder, S Weissmann, S Schnittger, W Kern, M C Müller, A Hochhaus, T Haferlach, C Haferlach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21274004     DOI： 10.1038/leu.2010.298

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  65 in total

Review 1.  Genetic events other than BCR-ABL1.

Authors:  Paolo Neviani
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

Review 2.  The argument for using imatinib in CML.

Authors:  Simone Claudiani; Jane F Apperley
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.

Authors:  Susanne Schnittger; Ulrike Bacher; Tamara Alpermann; Andreas Reiter; Madlen Ulke; Frank Dicker; Christiane Eder; Alexander Kohlmann; Vera Grossmann; Andreas Kowarsch; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

4.  Tyrosyl phosphorylation toggles a Runx1 switch.

Authors:  Benjamin G Neel; Nancy A Speck
Journal:  Genes Dev       Date:  2012-07-15       Impact factor: 11.361

5.  Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation.

Authors:  L Wang; A Howarth; R E Clark
Journal:  Leukemia       Date:  2014-03-12       Impact factor: 11.528

Review 6.  The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Authors:  Naranie Shanmuganathan; Susan Branford
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

7.  Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.

Authors:  Samantha B Foley; Zacariah L Hildenbrand; Abigail A Soyombo; Jeffery A Magee; Yipin Wu; Katherine I Oravecz-Wilson; Theodora S Ross
Journal:  Cell Rep       Date:  2013-10-03       Impact factor: 9.423

8.  Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.

Authors:  Konnie Hebeda; Ludmila Boudova; Christine Beham-Schmid; Attilio Orazi; Hans-Michael Kvasnicka; Umberto Gianelli; Alexandar Tzankov
Journal:  Ann Hematol       Date:  2020-10-31       Impact factor: 3.673

9.  Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Authors:  Véronique Gelsi-Boyer; Nathalie Cervera; François Bertucci; Mandy Brecqueville; Pascal Finetti; Anne Murati; Christine Arnoulet; Marie-Joelle Mozziconacci; Ken I Mills; Nicholas C P Cross; Norbert Vey; Daniel Birnbaum
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 10.  C/EBPα in normal and malignant myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.